If pharmaceutical company Allergan Inc serves as an accurate meter of the economic demand for cosmetic surgery, then perhaps things are looking up. First quarter earnings for the company (maker of Botox, Juvederm and Latisse) are way up. Second quarter forecasts, according to the Wall Street Journal, are ahead of expectations.
Success for the company shouldn’t be surprising, especially given the stats just released by the American Society of Plastic Surgeons. According to the society, minimally invasive procedures have increased a whopping 99 percent this decade. Topping the procedure list are wrinkle filler and botulinum toxin injections, two treatments in which plastic surgeons will likely utilize an Allergan product.
Image courtesy of the American Society of Plastic Surgeons
Being on the cutting-edge of aesthetic medicine doesn’t hurt either: demonstrated by the new “no-pain” Juvederm Ultra XC and the increasing popularity of Latisse, Allergan’s unique eyelash enhancement drug.
TWITTER
FACEBOOK
DR.'S BLOG
ONLINE